Related Experiment Video

Updated: May 27, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Molecular pathogenesis of pancreatic cancer and clinical perspectives

D Matthaios1, P Zarogoulidis, I Balgouranidou

  • 1Department of Medical Oncology, Democritus University of Thrace, Alexandroupolis, Greece.

Oncology
|November 26, 2011
PubMed

Insights

Pancreatic cancer

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic cancer exhibits significant molecular heterogeneity, contributing to resistance against current chemotherapies and targeted treatments.
  • Understanding this heterogeneity is crucial for developing effective therapeutic strategies.

Purpose of the Study:

  • To review pancreatic cancer's histological subtypes and their differentiation process from benign to malignant states.
  • To analyze key genes, molecular alterations, and pathways implicated in pancreatic cancer development and progression.
  • To present potential clinical interpretations and future therapeutic directions.

Main Methods:

  • Literature review focusing on pancreatic neoplasms.
  • Analysis of genetic mutations (e.g., p16/cdkn2a, k-ras, BRCA-2), molecular pathways (e.g., PI3K-AKT-mTOR, VEGF), and cellular processes (e.g., epithelial-to-mesenchymal transition).
  • Examination of epigenetic modifications, microRNA expression, and the role of pancreatic stellate cells.

Main Results:

  • Detailed elucidation of molecular events across various pancreatic tumor types.
  • Identification of specific genetic mutations and pathway dysregulations driving tumorigenesis.
  • Discussion of progression models and molecular underpinnings of therapeutic resistance.

Conclusions:

  • The molecular complexity of pancreatic cancer necessitates a multi-faceted approach to treatment.
  • Targeting specific molecular pathways and understanding histological subtypes may improve patient outcomes.
  • Future research should focus on novel therapeutic strategies informed by comprehensive molecular profiling.

More Related Videos

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Related Concept Videos

Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Acute Pancreatitis II: Pathophysiology01:21

Acute Pancreatitis II: Pathophysiology

The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...